- Myasthenia gravis neuropharmacological treatment.
Affected by myasthenia gravis in October, 1996, Dr. Fuad Lechin became
his own study case when he rejected the advise of U.S. experts to
undergo immunosuppressive therapy. He was submitted to neuroendocrine
plus immunological investigation, concluding he was severely stressed
(his profile was that registered in subjects maladapted to stress).
An antistress treatment to reduce both adreno-medullary secretion
and plasma serotonin levels and to rise central noradrenergic activity
provoked disappearance of symptoms within two weeks of starting treatment
on February 15, 1997. Up to the present, we have successfully treated
53 severe Myastenia Gravis patients with no failures or relapses.
- Crohnīs disease neuropharmacological treatment.
Sixteen severe cases over the past nine years have been treated successfully,
employing neuropharmacological agents to provoke progressive immunosuppression.
Serotonin releasing agent, serotonin precursors, dopaminergic blocking
agents, and central noradrenergic activity suppressors are the tools
Dr. Lechinīs team used as effective neuroimmunomodulators (see
- Ulcerative colitis (UC) neuropharmacological treatment.
Dr. Lechinīs research team was the first to demonstrate the antidiarrheic
effect of clonidine, dihydroergotamine, and other alpha adrenergic
antagonists, as well as dopaminergic blocking agents. All them suppress
rectal motility and rise sigmoidal tone (leading to constipation).
Although these drugs significantly improved symptoms in UC patients,
effective doses also provoked undesirable side effects. In order to
avoid UC exacerbation Dr. Lechinīs team introduced several neuropharmacological
immunosuppressant drugs which resulted very effective therapeutic
agents (see figures).
- Pancreatitis neuropharmacological treatment.
Both acute and chronic pancreatitis are successfully and dramatically
improved by alpha-2 agonist drugs. Normalization of amylase plasma
levels as well as clinical symptoms occur within the first 24-48 hours
of treatment. Dr. Lechinīs team has treated more than 15 patients.
- Irritable bowel syndrome neuropharmacological treatment.
Opposing pathophysiologic conditions make up the irritable bowel syndrome:
some patients show high distal colon motility plus rectal hypoactivity,
whereas other patients show low distal colon motility plus rectal
hyperactivity. The former, spastic colon, presents constipation, abdominal
pain and distention; it should be treated with serotonin releasing
drugs. The second, nervous diarrhea, is not accompanied by pain and
should be treated with alpha adrenergic blocking agents.
- Trigeminal neuralgia neuropharmacological treatment.
The neuroendocrine profile shown by trigeminal neuralgia sufferers
during attacks is that observed in maladapted to stress subjects.
Pain shows great improvement with drugs to increase central serotonergic
activity. Dopaminergic blocking agents are also dramatically effective
in treating trigeminal neuralgia. However, the use of these drugs
may provoke akathisia.
- Headache syndrome neuropharmacological treatment.
Tension headache patients show the typical neuroendocrine profile
of major depression, calling for treatment to reduce central noradrenergic
activity as well as augment central serotonergic activity.
Cluster headache patients show during exacerbation periods (migraine)
the maladapted stress profile: low central noradrenergic, serotonergic
and dopaminergic activity. Neuropharmacological therapy is required
to reverse these imbalances. It is also most important to reduce
plasma free serotonin levels provoked by raised platelet aggregation
registered in these patients during attacks.
- Hypoglycemia (postprandial or reactive) neuropharmacological
According to oral glucose tolerance tests, hypoglycemia patients fall
into two groups: those presenting typical maladapted to stress profile
(excessive adrenomedullary secretion), and those showing excess noradrenaline
plasma levels during this test. The former are greatly improved with
antistress treatment: potentiation of central noradrenergic activity
plus reduction of the increased free serotonin plasma levels found
in these patients. The second group is improved with drugs reducing
central noradrenergic activity plus drugs boosting central serotonergic
activity. This group presents the typical neuroendocrine profile of
- Infertility (non-organic) neuropharmacological treatment.
Infertility in women showing no organic causes has been suppressed
by neuropharmacological therapy to increase central dopaminergic activity.
Dr. Lechinīs research team has successfully treated more than 50 patients.
- Somatoform disorders neuropharmacological treatment.
This syndrome usually disappears with low dosis of dopaminergic blocking
agents (D2-antagonists). Dosification of plasma neurotransmitters
in these patients reveals raised dopamine levels (much higher than
- Cancer neuropharmacological treatment.
Our research group has treated some 2300 cancer patients during the
last 15 years, reporting significant improvement in all cases. Experimental
results have been partially published in journals and scientific congresses.
Dr. Lechin has visited cancer hospitals in USA (MD Anderson Cancer
Center at Houston, Arthur James Cancer Center at Ohio State University,
University of South Florida at Tampa, National Institute of Cancer
at Bethesda, Buenos Aires University Hospital, and many others) presenting
our cancer investigations.
Total disappearance of tumors and/or metastases have been observed
in most non advanced cancer patients following neuropharmacological
therapy. This type of therapy has proven to be 100% effective when
started immediately after adequate surgery. Those who have received
chemotherapy or radiotherapy responded less effectively, although
patients with lynphoma responded better when previously treated
with chemotherapy. Most effectivity was registered in cancer of
stomach, kidney, ovary, prostate gland and breast. One case of rabdomyosarcoma
(small intestine) was completely clear of cancer within 8 months
of treatment. Colon and lung cancer patients, as well as melanoma
patients, register great improvement but usually show tumor exacerbation
after two to five years. Poor response is observed in pancreatic
and esophageal cancer patients.
The neuropharmacological approach to cancer aims to normalize
the neuroendocrine plus immunological profile associated with maladapted
stress which these patients unfailingly present during exacerbation
periods. Thus it is necessary to control plasma neurotransmitters
(noradrenaline, adrenaline, dopamine, platelet serotonin, plasma
free serotonin and tryptophane); plasma hormones (cortisol, growth
hormone, prolactin); lymphocyte subsets, NK cell activity, etc.
The establishment of normal sleep profile is highly important
as immunoactivation is produced during delta sleep period. All drugs
provoking immunosuppresion must be avoided (benzodiazepines, opioids,
prostaglandin inhibitors, hormones, dopaminergic blocking agents,
serotonin releasing drugs, etc.).
Benzodiazepines and other hypnotics induce phases 1 and 2 of slow
wave sleep but interfere with phases 3 and 4 (delta sleep) and REM
Dopaminergic blocking agents have been found to provoke immunosuppression
and accelerate tumor growth and provoke the onset of metastasis.
- Post-traumatic stress disorder neuropharmacological treatment.
Dr. Lechinīs team found these patients show total exhaustion of central
noradrenergic, dopaminergic and serotonergic activity. They respond
to any small stress challenge with uncontrolled release of adreno-medullary
secretion. Neuropharmacology treatment to restore noradrenergic and
serotonergic activity should be undertaken slowly and progressively.
Large doses of neuro-active drug should be avoided as these patients
have supersensitive post-synaptic receptors.
- Osteoporosis neuropharmacological treatment.
Osteoporosis, even advanced cases, may be normalized through appropriate
neuropharmacological plus neuroendocrine manipulations to increase
GHRH and GH. Dr. Lechinīs team obtained positive results in all cases
they treated. They do not use other hormones like estrogens and progestogens.
- Akathisia neuropharmacological treatment.
This involuntary movement disorder, when found to be unresponsive
to biperiden administration, should be treated with drug which interfere
with the release of serotonin at synaptic level.
- Fibrocystic mastitis (mammary dysplasia) neuropharmacological
This disorder (with or without hyperprolactinemia) is associated with
a neurotransmitter profile compatible with low central dopaminergic
(DA) activity. Low doses of DA precursors and/or low doses of psychoactive
drugs which increase sensitivity of DA receptors are effective in
most cases. Dr. Lechinīs team has treated more than 50 cases.
- Hyperkinetic children (attention deficit disorder) neuropharmacological
Dr. Lechinīs team has found two types of neurochemical disorders underlying
this syndrome. One presents excessive free serotonin in the plasma
while the other shows excessive dopaminergic activity plus noradrenergic
overactivity. The former is improved with drugs favoring serotonin
uptake at the synaptic level. The second group is improved with serotonin
precursors. These treatments can be carried out in combination with
methylphenidate. Dr. Lechinīs team has treated more than 50 patients.
- Gilles de la Tourette disease neuropharmacological treatment.
Hyperdopaminergic activity underlies the physiological disorder of
this disease. However, low levels of serotonergic activity should
be consider as cofactor. This finding suggests that low level of serotonin
exists at the synaptic cleft. Results showing that these patients
are improved with dopaminergic antagonists plus serotonin precursors
plus serotonin potentiating drugs. Dr. Lechinīs team has treated 12
- Vertigo neuropharmacological treatment.
Most patients affected by this syndrome are wrongly diagnosed as labyrinthitis.
Dr. Lechinīs team has found that they have raised levels of free serotonin
in plasma. They improved dramatically upon increasing serotonin uptake
through neuropharmacological manipulation.